Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
For manufacturers in the Life Sciences industry, production challenges often occur in these four areas—production readiness, equipment reliability, personnel effectiveness and facility/line efficiency. In this post, I’ll focus on equipment reliability, and specifically, unplanned downtime.
In a presentation at the ACHEMA Pulse virtual conference this year, Emerson’s Alan Johnston shared how fast rollout of COVID vaccine manufacturing has changed the mindset of how quickly a new therapy can move from development to commercial manufacturing and ultimately to the consumer.
Accelerating vaccine development requires unprecedented flexibility in managing data. With increasing integration between product lifecycle management systems and software—like distributed control systems (DCS) and manufacturing execution systems (MES)—data, recipes, and processes can be digitally altered, shared, and used to scale across the lifecycle.
Technology has continued to advance and provide ways to assist pharmaceutical & biopharmaceutical manufacturers with production readiness. Improper set up and qualification of automation and information management production applications cause start-up and product changeover delays, as well as slow performance during production runs.
In a Pharmaceutical Processing World article, Emerson’s Ben Arriola and Zach Blum discuss technologies advancing vaccine development. It’s safe to say that there has never been a pharmaceutical effort so huge, fast, and successful as developing multiple vaccines for...
Personalized medicine manufacturers are rapidly changing their manufacturing platforms to provide a new scale of production. In the Emerson Exchange Virtual Series, life sciences experts held an open Q&A on the trajectory of cell and gene therapies, and how a...
A common theme across the Emerson Exchange Virtual Series has been the way software and digital technologies have helped us all deal with an unexpected and unprecedented pandemic. Wherever there is adversity, there are also innovators who step up to the challenge of...
In an Intech article, Three strategies help life sciences companies implement more successful review by exception, Emerson’s Emilee Cook shares ways for these manufacturers to improve this workflow.
Imagine driving the wrong direction for hundreds of miles after a wrong turn, simply because you didn’t notice missing the exit. Overlooked deviations can cause a lot of frustration, whether during a drive or while executing a batch of pharmaceuticals. Detecting and...
At the Biomanufacturing World Summit, Emerson’s Ron Rossbach presented on using digitalization and data integration to help drive operational efficiency. A key enabling technology for these performance gains is in real-time adaptive scheduling. This technology combines finite scheduling with dynamic updates from existing shop-floor execution systems to optimize operations. In 2018 Emerson acquired BioG, the leading provider of adaptive scheduling software, which is now being adopted across the industry.
The U.S. Food & Drug Administration (FDA) outlines the drug development process in five steps: Discovery and development Preclinical research Clinical trials FDA review FDA post-market safety monitoring I caught up with Emerson's Zuwei Jin whom you may recall from...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.
Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.
Our Global Community
Emerson Exchange 365
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.